tiprankstipranks
Advertisement
Advertisement

ZVSA Stock Latest News

ZyVersa Therapeutics Transitions to OTC Pink Market
Company AnnouncementsZyVersa Therapeutics Transitions to OTC Pink Market
18d ago
8K
ZVSA
ZyVersa Therapeutics Pursues Strategic Alternatives, Cuts Costs
PremiumCompany Announcements
ZyVersa Therapeutics Pursues Strategic Alternatives, Cuts Costs
24d ago
8K
ZVSA
ZyVersa Therapeutics Announces $1 Million Convertible Note Financing
PremiumCompany Announcements
ZyVersa Therapeutics Announces $1 Million Convertible Note Financing
5M ago
8K
ZVSA
Zyversa Therapeutics Faces Financial Challenges Amid Drug Development
PremiumCompany Announcements
Zyversa Therapeutics Faces Financial Challenges Amid Drug Development
9M ago
ZVSA
ZyVersa Therapeutics Delays 10-Q Filing
PremiumCompany Announcements
ZyVersa Therapeutics Delays 10-Q Filing
9M ago
ZVSA
Zyversa Therapeutics’ Promising Phase 2a Study on DKD Treatment
PremiumCompany AnnouncementsZyversa Therapeutics’ Promising Phase 2a Study on DKD Treatment
9M ago
ZVSA
ZyVersa Therapeutics Faces Nasdaq Delisting Notice
Premium
Company Announcements
ZyVersa Therapeutics Faces Nasdaq Delisting Notice
11M ago
8K
ZVSA
ZyVersa Therapeutics highlights publication of data on inflammasome inhibitors
Premium
The Fly
ZyVersa Therapeutics highlights publication of data on inflammasome inhibitors
11M ago
ZVSA
ZyVersa Therapeutics highlights lipidomic data in Alport Syndrome, DKD
PremiumThe Fly
ZyVersa Therapeutics highlights lipidomic data in Alport Syndrome, DKD
11M ago
ZVSA
ZyVersa Therapeutics Reports Financial Challenges Amid Nasdaq Delisting
PremiumCompany Announcements
ZyVersa Therapeutics Reports Financial Challenges Amid Nasdaq Delisting
12M ago
ZVSA
ZyVersa Therapeutics highlights data on role of lipotoxicity in DKD
PremiumThe Fly
ZyVersa Therapeutics highlights data on role of lipotoxicity in DKD
12M ago
ZVSA
ZyVersa Therapeutics reports Q2 EPS (46c) vs. ($3.31) last year
PremiumThe Fly
ZyVersa Therapeutics reports Q2 EPS (46c) vs. ($3.31) last year
12M ago
ZVSA
ZyVersa Therapeutics expects cash to fund requirements on month-to-month basis
PremiumThe FlyZyVersa Therapeutics expects cash to fund requirements on month-to-month basis
12M ago
ZVSA
ZyVersa Therapeutics Stock Approved for OTCQB Listing
Premium
Company Announcements
ZyVersa Therapeutics Stock Approved for OTCQB Listing
1y ago
8K
ZVSA
ZyVersa CEO says ‘deeply committed’ to executing with discipline, urgency
Premium
The Fly
ZyVersa CEO says ‘deeply committed’ to executing with discipline, urgency
1y ago
ZVSA
ZyVersa Therapeutics Faces Nasdaq Delisting, Plans Pink Market Move
PremiumCompany Announcements
ZyVersa Therapeutics Faces Nasdaq Delisting, Plans Pink Market Move
1y ago
8K
ZVSA
ZyVersa Therapeutics Enters Warrant Exercise Agreement
PremiumCompany Announcements
ZyVersa Therapeutics Enters Warrant Exercise Agreement
1y ago
8K
ZVSA
ZyVersa announces warrant inducement transaction for $2M in gross proceeds
PremiumThe Fly
ZyVersa announces warrant inducement transaction for $2M in gross proceeds
1y ago
ZVSA
ZyVersa supports FDA-authorized Emergency Compassionate Use of VAR 200
PremiumThe Fly
ZyVersa supports FDA-authorized Emergency Compassionate Use of VAR 200
1y ago
ZVSA
ZyVersa Therapeutics files to sell 17.5M shares of common stock for holders
PremiumThe FlyZyVersa Therapeutics files to sell 17.5M shares of common stock for holders
1y ago
ZVSA
ZyVersa announces first clinical site activation in VAR 200 Phase 2a trial
Premium
The Fly
ZyVersa announces first clinical site activation in VAR 200 Phase 2a trial
1y ago
ZVSA
ZyVersa Therapeutics Secures $10M Equity Purchase Agreement
Premium
Company Announcements
ZyVersa Therapeutics Secures $10M Equity Purchase Agreement
1y ago
8K
ZVSA

Trending

Name
Price
Price Change
SPX
S&P 500
―
DJIA
Dow Jones
―
NDX
Nasdaq 100
―
More Trending Stocks >